Frontiers in Immunology (Feb 2024)

T cell senescence: a new perspective on immunotherapy in lung cancer

  • Mengge Huang,
  • Yuetong Wang,
  • Liguang Fang,
  • Cun Liu,
  • Fubin Feng,
  • Lijuan Liu,
  • Changgang Sun,
  • Changgang Sun

DOI
https://doi.org/10.3389/fimmu.2024.1338680
Journal volume & issue
Vol. 15

Abstract

Read online

T cell senescence is an indication of T cell dysfunction. The ability of senescent T cells to respond to cognate antigens is reduced and they are in the late stage of differentiation and proliferation; therefore, they cannot recognize and eliminate tumor cells in a timely and effective manner, leading to the formation of the suppressive tumor microenvironment. Establishing methods to reverse T cell senescence is particularly important for immunotherapy. Aging exacerbates profound changes in the immune system, leading to increased susceptibility to chronic, infectious, and autoimmune diseases. Patients with malignant lung tumors have impaired immune function with a high risk of recurrence, metastasis, and mortality. Immunotherapy based on PD-1, PD-L1, CTLA-4, and other immune checkpoints is promising for treating lung malignancies. However, T cell senescence can lead to low efficacy or unsuccessful treatment results in some immunotherapies. Efficiently blocking and reversing T cell senescence is a key goal of the enhancement of tumor immunotherapy. This study discusses the characteristics, mechanism, and expression of T cell senescence in malignant lung tumors and the treatment strategies.

Keywords